Ποια είναι η τιμή για Reviva Pharmaceuticals Holdings, Inc. (RVPHW)

Η τιμή για Reviva Pharmaceuticals Holdings, Inc. (RVPHW) είναι $0.003

Ποια είναι η κεφαλαιοποίηση αγοράς για Reviva Pharmaceuticals Holdings, Inc. (RVPHW)

Η κεφαλαιοποίηση αγοράς για Reviva Pharmaceuticals Holdings, Inc. (RVPHW) είναι $343.91K

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) Ιστορικό Τιμών

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for diseases with substantial unmet medical needs. Their pipeline targets disorders within the central nervous system, respiratory, cardiovascular, metabolic, and inflammatory disease categories. The company's leading drug candidate, brilaroxazine (RP5063), is currently in Phase III clinical trials for the treatment of schizophrenia. This compound has also completed Phase I trials for a diverse set of conditions, including bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, the behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. Furthermore, Reviva is advancing RP1208, which is in pre-clinical development for depression and obesity. Founded in 2018, the company is headquartered in Cupertino, California.

Έτος	Απόδοση
2026 (TTM)	305.88%
2025	-96.70%
2024	-75.67%
2023	0.82%
2022	134.68%
2021	-39.09%
2020	167.36%
2019	-15.00%
2018	0.00%

Έτος

Απόδοση

2026 (TTM)

305.88%

2025

-96.70%

2024

-75.67%

2023

0.82%

2022

134.68%

2021

-39.09%

2020

167.36%

2019

-15.00%

2018

0.00%

Εταιρεία	Τιμή μετοχής	Μεταβολή 1Έτ%	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$517.18	32.51%	US
Argenx SE ARGX.US	$857.76	31.47%	NL
Lonza Group AG LONN.SW	$744.96	9.07%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.27%	KR
UCB S.A. UCB.BR	$259.89	14.81%	BE

Εταιρεία

Τιμή μετοχής

Μεταβολή 1Έτ%

Χώρα